Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1992-11-19
1995-03-28
Kepplinger, Esther M.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 165, 424 181, 424 185, 424 9, 435 6, 514 25, 514398, A61K 4902, A61K 31415, C12Q 168
Patent
active
054014905
ABSTRACT:
Novel nucleosides are provided having at least one hydrogen or hydroxide substitutent replaced by a .gamma.-emitting halogen. Methods of preparation of these nucleosides are provided and also a novel non-invasive method for the detection and measurement of tissue hypoxia in mammals.
REFERENCES:
patent: 4462992 (1984-07-01), Agrawal et al.
Wiebe et al "Iodoazomycin Riboside [1-(5'-iodo-5'-deoxyribofuranosyl)-2-nitroimidazole], a Hypoxic Cell Marker In Vivo Evaluation in Experimental Tumors" in Nuclear Medicine in Clinical Oncology Ed. by C Winkler, Springer-Verlag (1986) pp. 402-407.
"Biochemistry of Reduction of Nitro Heterocycles"; John E. Biaglow, et al.; pp. 77-90.
"Contribution of Radionuclide Imaging to Radiation Oncology"; Carl M. Mansfield and Chan H. Park; Seminars in Nuclear Medicine; vol. XV, No. 1 (Jan, 1985); pp. 28-45.
"Radiosensitizers: Rationale and Potential"; J. Martin Brown; Cancer Treatment Reports; vol. 65 (Suppl. 2), 1981; pp. 95-102.
"Sucralose Overview"; Splenda.RTM. Brand Sweetner, pp. 1-10.
Chapman John D.
Mannan Rezaul H.
Mercer John R.
Somayaji Vijayalakashmi
Wiebe Leonard I.
Alberta Cancer Board
Green Lora M.
Kepplinger Esther M.
LandOfFree
Markers of tissue hypoxia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Markers of tissue hypoxia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Markers of tissue hypoxia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2248740